Radboud UMC, Nijmegen & Andriessen Consultants, Malden, The Netherlands.
International Compression Club (ICC), Berndorf, Austria.
J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1562-1568. doi: 10.1111/jdv.14390. Epub 2017 Jul 31.
The adequate use of compression in venous leg ulcer treatment is equally important to patients as well as clinicians. Currently, there is a lack of clarity on contraindications, risk factors, adverse events and complications, when applying compression therapy for venous leg ulcer patients.
The project aimed to optimize prevention, treatment and maintenance approaches by recognizing contraindications, risk factors, adverse events and complications, when applying compression therapy for venous leg ulcer patients. A literature review was conducted of current guidelines on venous leg ulcer prevention, management and maintenance.
Searches took place from 29th February 2016 to 30th April 2016 and were prospectively limited to publications in the English and German languages and publication dates were between January 2009 and April 2016. Twenty Guidelines, clinical pathways and consensus papers on compression therapy for venous leg ulcer treatment and for venous disease, were included. Guidelines agreed on the following absolute contraindications: Arterial occlusive disease, heart failure and ankle brachial pressure index (ABPI) <0.5, but gave conflicting recommendations on relative contraindications, risks and adverse events. Moreover definitions were unclear and not consistent.
Evidence-based guidance is needed to inform clinicians on risk factor, adverse effects, complications and contraindications. ABPI values need to be specified and details should be given on the type of compression that is safe to use. Ongoing research challenges the present recommendations, shifting some contraindications into a list of potential indications. Complications of compression can be prevented when adequate assessment is performed and clinicians are skilled in applying compression.
在静脉溃疡治疗中,适当使用压缩疗法对患者和临床医生同样重要。目前,在为静脉溃疡患者应用压缩疗法时,对于禁忌证、风险因素、不良事件和并发症,尚无明确的认识。
本项目旨在通过认识禁忌证、风险因素、不良事件和并发症,优化静脉溃疡预防、治疗和维持的方法。对静脉溃疡预防、管理和维持的现行指南进行了文献回顾。
检索时间为 2016 年 2 月 29 日至 2016 年 4 月 30 日,前瞻性地仅限于英文和德文出版物,出版日期为 2009 年 1 月至 2016 年 4 月。共纳入 20 项关于静脉溃疡治疗和静脉疾病的压缩治疗指南、临床路径和共识文件。指南均同意以下绝对禁忌证:动脉阻塞性疾病、心力衰竭和踝肱血压指数(ABI)<0.5,但对相对禁忌证、风险和不良事件的建议存在分歧。此外,定义不明确且不一致。
需要有循证指导来为临床医生提供有关风险因素、不良影响、并发症和禁忌证的信息。ABI 值需要具体说明,并且应该详细说明使用安全的压缩类型。正在进行的研究对现有建议提出了挑战,将一些禁忌证列入潜在适应证清单。当进行充分评估且临床医生熟练应用压缩疗法时,可预防并发症。